Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice

Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Authors

ČERVINEK Libor CERNA Olga ČANIGA Miroslav KONIROVA Eva HLUŠÍ Antonín SIMKOVIC Martin POSPÍŠIL Zdeněk CERMAK Jaroslav KOZÁK Tomáš MAYER Jiří DOUBEK Michael

Year of publication 2012
Type Article in Periodical
Magazine / Source International journal of hematology
MU Faculty or unit

Central European Institute of Technology

Citation
Web http://link.springer.com/content/pdf/10.1007%2Fs12185-012-1206-7
Doi http://dx.doi.org/10.1007/s12185-012-1206-7
Field Oncology and hematology
Keywords Adults; Immune thrombocytopenia; Response rate; Rituximab
Attached files
Description Although rituximab has seen increasing use in the treatment of immune thrombocytopenia (ITP) for many years, its therapeutic role in this disease remains unclear. We retrospectively analyzed data of all patients with ITP treated with rituximab (375 mg/m(2) once weekly for four consecutive weeks) and consecutively entered the findings into the databases of six large academic centers in the Czech Republic. A total of 114 patients were included in the analysis. All of the patients received rituximab as a second or additional line of therapy. The overall response rate (ORR) after rituximab therapy was 72 % [48 % complete response (CR), 24 % partial response (PR)] at month 6, and 69 % (45 % CR, 24 % PR) at month 12. For the group of patients with newly diagnosed (acute) ITP, the results of treatment were significantly better than for the group of patients with persistent or chronic ITP; nonetheless, this group of patients was far too small (n = 18) for our findings to be generalized. Multivariate analysis revealed that the ORR was significantly influenced primarily by the number of therapies prior to rituximab (the more previous therapies, the worse treatment response). The results of our analysis "from everyday hematological practice" confirm the high efficiency of rituximab treatment in pretreated adult patients with ITP.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info